PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 900481-0 1977 A simplified procedure for the concentration, desalting, and thin-layer chromatography of mevalonic acid from reaction mixtures used to assay 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Mevalonic Acid 90-104 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 142-189 33109681-1 2020 HMG-CoA Reductase (Hmgcr) is the rate-limiting enzyme in the mevalonate pathway and is inhibited by statins. Mevalonic Acid 61-71 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Mevalonic Acid 113-123 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-71 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Mevalonic Acid 113-123 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-78 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Mevalonic Acid 125-128 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-71 33992804-3 2021 Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Mevalonic Acid 125-128 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-78 33307558-1 2021 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway, which generates cholesterol and non-sterol compounds such as isoprenoid, which are involved in key steps of tumorigenesis such as cell growth and proliferation. Mevalonic Acid 91-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 33307558-1 2021 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway, which generates cholesterol and non-sterol compounds such as isoprenoid, which are involved in key steps of tumorigenesis such as cell growth and proliferation. Mevalonic Acid 91-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 49-54 33109681-1 2020 HMG-CoA Reductase (Hmgcr) is the rate-limiting enzyme in the mevalonate pathway and is inhibited by statins. Mevalonic Acid 61-71 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-24 31685796-7 2019 Moreover, clinical data revealed better prognosis in patients with high levels of ASPP2 and low levels of the mevalonate pathway enzyme HMGCR. Mevalonic Acid 110-120 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 136-141 32887721-1 2020 Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway. Mevalonic Acid 129-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-87 32887721-1 2020 Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway. Mevalonic Acid 129-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 89-94 32887721-1 2020 Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway. Mevalonic Acid 141-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-87 32887721-1 2020 Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway. Mevalonic Acid 141-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 89-94 32758903-4 2020 As competitive inhibitors of HMG-CoA-reductase, the key enzyme of the "mevalonate pathway" through which essential compounds, not only cholesterol, are synthesized, statins decrease the levels of cholesterol, and thus LDLs, as an innate defense mechanism, with controversial results in decreasing mortality from cardiovascular disease. Mevalonic Acid 71-81 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 29-46 33059448-5 2020 BRs can negatively regulate the expression of VvHMGR, a key gene involved in the mevalonate (MVA) pathway, and reduce the activity of 3-hydroxy-3-methylglutaryl CoA reductase (HMGR). Mevalonic Acid 81-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-52 33110395-4 2020 These drugs act inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, the limiting step in cholesterol biosynthesis. Mevalonic Acid 140-150 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-84 33110390-3 2020 Statins inhibit the HMGCR (rate-limiting enzyme) activity in early stages of mevalonate pathway and then indirectly affect a number of intermediate products, including non-sterol isoprenoids (coenzyme Q10, dolichol etc. Mevalonic Acid 77-87 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 20-25 32004772-1 2020 Fluvastatin and atorvastatin are inhibitors of hydroxy-methylglutaryl-CoA (HMG-CoA) reductase, the enzyme that converts HMG-CoA to mevalonic acid (MVA). Mevalonic Acid 131-145 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-93 32004772-1 2020 Fluvastatin and atorvastatin are inhibitors of hydroxy-methylglutaryl-CoA (HMG-CoA) reductase, the enzyme that converts HMG-CoA to mevalonic acid (MVA). Mevalonic Acid 147-150 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-93 32974183-3 2020 SREBP-2 binds to the sterol regulatory elements (SREs) in the promoters of its target genes and activates the transcription of mevalonate pathway genes, such as HMG-CoA reductase (HMGCR), mevalonate kinase and other key enzymes. Mevalonic Acid 127-137 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 161-178 32974183-3 2020 SREBP-2 binds to the sterol regulatory elements (SREs) in the promoters of its target genes and activates the transcription of mevalonate pathway genes, such as HMG-CoA reductase (HMGCR), mevalonate kinase and other key enzymes. Mevalonic Acid 127-137 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 180-185 32974183-5 2020 We then found that SREBP-2 and its regulated enzymes, including HMGCR, FPPS, SQS, and DHCR4 from the mevalonate pathway, participate in the progression of various cancers, including prostate, breast, lung, and hepatocellular cancer, as potential targets. Mevalonic Acid 101-111 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 64-69 31963885-3 2020 Studies showed that T3 could prevent various NCDs, by suppressing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in the mevalonate pathway, inflammatory response, oxidative stress, and alternating hormones. Mevalonic Acid 129-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-113 31963885-3 2020 Studies showed that T3 could prevent various NCDs, by suppressing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in the mevalonate pathway, inflammatory response, oxidative stress, and alternating hormones. Mevalonic Acid 129-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 115-120 31554629-4 2019 In this study, we found that fluvastatin targeted 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), which a rate-limiting enzyme in the mevalonate pathway, and inhibited non-small cell lung cancer (NSCLC) tumorigenesis. Mevalonic Acid 153-163 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 109-114 31631207-5 2019 Our analyses further reveal that 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is the rate-determining enzyme of the mevalonate pathway, is a novel target of auranofin with half maximal inhibitory concentration at micromolar levels. Mevalonic Acid 134-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 33-80 31737505-3 2019 Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway. Mevalonic Acid 98-108 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-56 31737505-3 2019 Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway. Mevalonic Acid 98-108 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-63 31023626-1 2019 OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR). Mevalonic Acid 155-165 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 181-198 31023626-1 2019 OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR). Mevalonic Acid 155-165 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 200-205 31023626-1 2019 OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR). Mevalonic Acid 167-170 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 181-198 31023626-1 2019 OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR). Mevalonic Acid 167-170 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 200-205 31316383-1 2019 Statins efficiently inhibit cholesterol synthesis by blocking 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the mevalonate pathway. Mevalonic Acid 116-126 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-108 31026757-10 2019 Mevalonate mitigated the effects of lovastatin, suggesting that the targeting of CSCs by lovastatin was mediated by the inhibition of its reported target, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR). Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 155-203 31026757-10 2019 Mevalonate mitigated the effects of lovastatin, suggesting that the targeting of CSCs by lovastatin was mediated by the inhibition of its reported target, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR). Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 205-210 31455613-0 2019 Endogenous sterol intermediates of the mevalonate pathway regulate HMG-CoA reductase degradation and SREBP-2 processing. Mevalonic Acid 39-49 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 67-84 31455613-5 2019 With a constructed HeLa cell line expressing the mevalonate transporter, we individually deleted genes encoding major enzymes in the mevalonate pathway, used lipidomics to measure sterol intermediates, and examined HMGCR and SREBP-2 statuses. Mevalonic Acid 49-59 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 215-220 31631207-5 2019 Our analyses further reveal that 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is the rate-determining enzyme of the mevalonate pathway, is a novel target of auranofin with half maximal inhibitory concentration at micromolar levels. Mevalonic Acid 134-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-87 30702149-1 2019 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyses the last step in mevalonate biosynthesis. Mevalonic Acid 75-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-40 30787037-5 2019 The mevalonate pathway is modifiable through the enzyme 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMGCo-A) reductase. Mevalonic Acid 4-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-114 30787037-6 2019 This enzyme controls the rate limiting step of the mevalonate pathway and is subject to inhibition by statin drugs (HMGCo-A reductase inhibitors) and small chain fatty acids derived from high dietary fiber intake. Mevalonic Acid 51-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 116-133 30765461-4 2019 The mevalonate [3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase] pathway synthesizes lipids for G-protein prenylation. Mevalonic Acid 4-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-73 30702149-1 2019 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyses the last step in mevalonate biosynthesis. Mevalonic Acid 75-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-46 30829216-1 2019 During intrinsic cholesterol formation 3-hydroxy-3-methylgutaryl coenzyme A reductase (HMGCR) converts HMGCoA to mevalonate, in biosynthetic cascade of cholesterol. Mevalonic Acid 113-123 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 87-92 30551403-4 2019 Statins, inhibitors of the key enzyme of mevalonate pathway HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase are drugs commonly prescribed in order to reduce serum level of cholesterol and to diminish the risk of cardiovascular disease. Mevalonic Acid 41-51 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 69-118 29923256-2 2018 Statins halt hepatic cholesterol biosynthesis by inhibiting the rate-limiting enzyme in the mevalonate pathway, hydroxymethylglutaryl-coenzyme A reductase (HMGCR). Mevalonic Acid 92-102 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 112-154 30619997-2 2019 Cell culture studies have shown that AMPK phosphorylation and inhibition of the rate-limiting enzyme in the mevalonate pathway 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) reductase (HMGCR) at serine-871 (Ser871; human HMGCR Ser872) suppresses cholesterol synthesis. Mevalonic Acid 108-118 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 188-193 30619997-2 2019 Cell culture studies have shown that AMPK phosphorylation and inhibition of the rate-limiting enzyme in the mevalonate pathway 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) reductase (HMGCR) at serine-871 (Ser871; human HMGCR Ser872) suppresses cholesterol synthesis. Mevalonic Acid 108-118 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 224-229 29923256-2 2018 Statins halt hepatic cholesterol biosynthesis by inhibiting the rate-limiting enzyme in the mevalonate pathway, hydroxymethylglutaryl-coenzyme A reductase (HMGCR). Mevalonic Acid 92-102 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 156-161 29899021-4 2018 By blocking mevalonate production, HMGCR inhibition suppressed protein geranylgeranylation, resulting in up-regulation of proapoptotic protein p53 up-regulated modulator of apoptosis (PUMA). Mevalonic Acid 12-22 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-40 29890243-3 2018 They are currently used to treat hypercholesterolemia by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, that catalyses the rate limiting step in the mevalonate biosynthesis pathway, a key intermediate in cholesterol metabolism. Mevalonic Acid 176-186 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 72-129 30106444-5 2018 Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells. Mevalonic Acid 90-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 30089652-4 2018 In the present study, we found that 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), a crucial enzyme in the mevalonate pathway for sterol biosynthesis, is elevated in enzalutamide-resistant prostate cancer cell lines. Mevalonic Acid 111-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-77 30089652-4 2018 In the present study, we found that 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), a crucial enzyme in the mevalonate pathway for sterol biosynthesis, is elevated in enzalutamide-resistant prostate cancer cell lines. Mevalonic Acid 111-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-84 30034619-4 2018 Thus, combined inhibition of the mevalonate pathway"s rate-limiting enzyme, HMGCR, can improve atorvastatin"s growth inhibitory effect on epithelial- and mixed mesenchymal-epithelial cancer cells, a finding that may have implications for the design of future anti-metastatic cancer therapies. Mevalonic Acid 33-43 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 76-81 29445111-3 2018 Using Auditory Brainstem Responses (ABR) in a guinea pig model, we demonstrate that fluvastatin, an inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, protects against loss of cochlear function initiated by high intensity noise. Mevalonic Acid 164-174 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 113-130 29575963-6 2018 Areas covered: HMGCR is in the mevalonate (MA) pathway and MA signaling is fundamental to lung biology and asthma. Mevalonic Acid 31-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-20 29765517-5 2018 Inhibition of the mevalonate pathway by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), resulted in reduced expression of FoxM1 and increased cell death in human hepatoma cells. Mevalonic Acid 18-28 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-103 29765517-5 2018 Inhibition of the mevalonate pathway by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), resulted in reduced expression of FoxM1 and increased cell death in human hepatoma cells. Mevalonic Acid 18-28 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-110 29765517-6 2018 Re-exposure of mevalonate, a product of HMGCR, restored these effects. Mevalonic Acid 15-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 40-45 29765517-7 2018 Likewise, knockdown of HMGCR reduced FoxM1 expression, indicating that FoxM1 expression was regulated by the mevalonate pathway in HCC. Mevalonic Acid 109-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-28 29765517-9 2018 In surgically resected human HCC tissues, the gene expression of FoxM1 had a positive correlation with that of the mevalonate pathway-related genes, such as HMGCR or sterol regulatory element-binding protein 2 (SREBP2). Mevalonic Acid 115-125 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 157-162 29765517-10 2018 Furthermore, the gene expression of FoxM1 along with that of HMGCR or SREBP2 defined prognosis of HCC patients, suggesting the clinical significance of the mevalonate-FoxM1 pathway in human HCC. Mevalonic Acid 156-166 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 61-66 30237809-2 2018 Statins target the mevalonate pathway by blocking HMG-CoA reductase. Mevalonic Acid 19-29 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 50-67 29683099-9 2018 Statins, a well-known class of cholesterol-lowering agents, inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in the mevalonate pathway. Mevalonic Acid 163-173 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 68-126 28362175-1 2017 The growth-suppressive effect of d-delta-tocotrienol and geranylgeraniol is at least partially attributed to their impact on 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting enzyme in the mevalonate pathway that provides essential intermediates for the posttranslational modification of growth-related proteins including RAS. Mevalonic Acid 216-226 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 125-182 29039527-2 2017 They act by inhibiting 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate. Mevalonic Acid 120-130 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-73 29163687-0 2017 Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR. Mevalonic Acid 53-63 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 91-96 29163687-5 2017 Genes upregulated in normal human prostate stromal cells (PrSC) co-cultured with human PC cells (LNCaP) included the mevalonate pathway enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). Mevalonic Acid 117-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 199-239 29163687-5 2017 Genes upregulated in normal human prostate stromal cells (PrSC) co-cultured with human PC cells (LNCaP) included the mevalonate pathway enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). Mevalonic Acid 117-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 241-246 28668359-2 2017 Statins through inhibition of Hydroxy Methyl Glutaryl-CoA Reductase (HMGCR), the main enzyme of the cholesterol biosynthesis pathway, inhibit mevalonate pathway that provides isoprenoids for prenylation of different proteins such as Ras superfamily which has an essential role in cancer developing. Mevalonic Acid 142-152 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-67 28668359-2 2017 Statins through inhibition of Hydroxy Methyl Glutaryl-CoA Reductase (HMGCR), the main enzyme of the cholesterol biosynthesis pathway, inhibit mevalonate pathway that provides isoprenoids for prenylation of different proteins such as Ras superfamily which has an essential role in cancer developing. Mevalonic Acid 142-152 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 69-74 31156928-3 2017 It inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which converts HMG-CoA into mevalonic acid, a cholesterol precursor. Mevalonic Acid 98-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 12-69 29077483-3 2017 Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway. Mevalonic Acid 163-177 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 77-117 29077483-3 2017 Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway. Mevalonic Acid 163-177 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 119-124 29077483-3 2017 Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway. Mevalonic Acid 181-191 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 77-117 29077483-3 2017 Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway. Mevalonic Acid 181-191 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 119-124 28710496-6 2017 Pitavastatin-induced apoptosis was blocked by geranylgeraniol and mevalonate, products of the HMGCR pathway, confirming that pitavastatin causes cell death through inhibition of HMGCR. Mevalonic Acid 66-76 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 94-99 26758944-5 2017 The mevalonate pathway is readily and substantially modified by inhibition of the enzyme 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMGCo-A) reductase. Mevalonic Acid 4-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 129-147 26758951-4 2017 Statins are inhibitors of HMG-CoA reductase, the enzyme that catalyzes the reduction of HMG-CoA to mevalonic acid by NADPH. Mevalonic Acid 99-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 26-43 25936991-3 2015 It has been reported that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ameliorate glomerular injury in several experimental models of progressive glomerular disease by inhibiting the production of MVA and its metabolites. Mevalonic Acid 211-214 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 26-73 27335167-7 2016 The inhibitory effect of simvastatin on atrial fibroblasts was abrogated by mevalonic acid (500 muM) that bypasses 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition. Mevalonic Acid 76-90 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 115-172 26432005-2 2016 Mevalonate pathway and its rate-limiting enzyme HMG-CoA reductase (HMGCR) have shown important roles in the progression of several cancer types. Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-65 26432005-2 2016 Mevalonate pathway and its rate-limiting enzyme HMG-CoA reductase (HMGCR) have shown important roles in the progression of several cancer types. Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 67-72 28132458-3 2016 They act by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (EC 1.1.1.88), the first committed enzyme of the mevalonate pathway. Mevalonic Acid 144-154 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-94 26358205-1 2015 Statins exhibit anti-leukemic properties due to suppression of the mevalonate pathway by the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase, and subsequent depletion of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate. Mevalonic Acid 67-77 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 107-154 25759117-3 2015 Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H). Mevalonic Acid 102-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 129-169 25759117-3 2015 Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H). Mevalonic Acid 102-112 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 171-176 25759117-9 2015 In conclusion, we quantitatively delineate proteomic and transcriptional levels of IFN-mediated control of HMGCR, the primary enzymatic step of the mevalonate-sterol biosynthesis pathway, providing a foundational framework for mathematically modelling the therapeutic outcome of immune-metabolic pathways. Mevalonic Acid 148-158 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 107-112 27585573-2 2016 Feedback inhibition of HMGCoA reductase (HMGCR) catalytic activity in the transformation of HMG-CoA to mevalonate is a significant regulatory step in sterol biosynthetic pathway. Mevalonic Acid 103-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-39 27585573-2 2016 Feedback inhibition of HMGCoA reductase (HMGCR) catalytic activity in the transformation of HMG-CoA to mevalonate is a significant regulatory step in sterol biosynthetic pathway. Mevalonic Acid 103-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-46 27155373-2 2016 The mevalonate cascade and its rate-liming enzyme HMG CoA-reductase has recently drawn the attention of cancer researchers because strong evidences arising mostly from epidemiologic studies, show that it could promote transformation. Mevalonic Acid 4-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 50-67 25607255-1 2015 Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is a rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 122-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 26-73 25977402-1 2015 Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is involved in the production of mevalonic acid in the cholesterol biosynthesis pathway. Mevalonic Acid 125-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-84 26109908-2 2015 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. Mevalonic Acid 91-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 26109908-2 2015 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. Mevalonic Acid 91-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 49-54 25862838-4 2015 Statins inhibit the mevalonate pathway at 3-hydroxy-3-methylglutaryl coenzyme A reductase and bisphosphonates at farnesyl pyrophosphate synthase. Mevalonic Acid 20-30 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-89 25745361-3 2015 Here we show that atorvastatin (Lipitor), an inhibitor of hydroxymethylglutaryl co-enzyme A (HMG-CoA) reductase that is a rate-limiting enzyme of mevalonate pathway, down-regulates expression of PBK by impairing protein geranylgeranylation. Mevalonic Acid 146-156 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-111 25607255-1 2015 Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is a rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 122-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-80 25497898-2 2015 Farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) are derived from mevalonate, whose production is catalyzed by 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. Mevalonic Acid 84-94 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 129-179 24548821-2 2014 However, considering that the pharmacological target of statins, the 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase, is one of the upstream enzyme of the mevalonate pathway, its inhibition may determine a substantial impoverishment of additional lipid moieties required for a proper cellular function. Mevalonic Acid 168-178 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 69-129 25311809-5 2014 Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway, by lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell activation via CD40 and impaired their ability to act as stimulatory APCs for allospecific T cells. Mevalonic Acid 88-98 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-54 24390662-1 2014 Hydroxymethylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme of mevalonate pathway, has been involved in the tumorigenesis of several tumor types. Mevalonic Acid 80-90 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-42 24637330-1 2014 HMG-CoA reductase, the proximal rate-limiting enzyme in the mevalonate pathway, is inhibited by statins. Mevalonic Acid 60-70 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 24582968-4 2014 Because all cells require a steady supply of MVA, both the sterol (i.e. cholesterol) and non-sterol (i.e. isoprenoid) products of MVA metabolism exert coordinated feedback regulation on HMGCR through different mechanisms. Mevalonic Acid 45-48 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 186-191 24732207-2 2014 The HMGCR transcripts are detectable during early embryogenesis in both invertebrates and vertebrates, which suggests a conserved developmental requirement for mevalonate derivatives. Mevalonic Acid 160-170 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-9 24777857-4 2014 The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 106-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 47-64 24777857-4 2014 The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 106-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-71 24295174-2 2014 Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase, the major rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid. Mevalonic Acid 161-175 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 67-85 24390662-1 2014 Hydroxymethylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme of mevalonate pathway, has been involved in the tumorigenesis of several tumor types. Mevalonic Acid 80-90 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 44-49 24806902-1 2014 BACKGROUND: Mevalonic acid (MVA), as a product of 3-hydroxy-3-methylglutaryl coenzyme A reductase, represents a potential multipurpose biomarker in health and disease. Mevalonic Acid 12-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 50-97 24806902-1 2014 BACKGROUND: Mevalonic acid (MVA), as a product of 3-hydroxy-3-methylglutaryl coenzyme A reductase, represents a potential multipurpose biomarker in health and disease. Mevalonic Acid 28-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 50-97 23386644-9 2013 CONCLUSIONS: Resveratrol inhibits key steps of the mevalonate pathway by mechanisms that are partly complementary to and partly comparable with simvastatin via reducing both expression and activity of HMGCR. Mevalonic Acid 51-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 201-206 24333427-1 2014 Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions. Mevalonic Acid 136-150 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-42 24333427-1 2014 Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions. Mevalonic Acid 136-150 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 44-49 24333427-1 2014 Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions. Mevalonic Acid 152-155 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-42 24333427-1 2014 Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions. Mevalonic Acid 152-155 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 44-49 23554170-9 2013 Neuronal expression of APP decreased both HMGCR and cholesterol 24-hydroxylase mRNA levels and consequently cholesterol turnover, leading to inhibition of neuronal activity, which was rescued by geranylgeraniol, generated in the mevalonate pathway, in both APP expressing and mevastatin treated neurons. Mevalonic Acid 229-239 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-47 24270073-1 2014 The enzyme 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGR) catalyzes the conversion of HMG-Co-A into mevalonate. Mevalonic Acid 108-118 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 11-58 24386216-1 2013 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is a rate-controlling enzyme in the mevalonate pathway which involved in biosynthesis of cholesterol and other isoprenoids. Mevalonic Acid 91-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 24006306-1 2013 The rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides essential intermediates for the prenylation of nuclear lamins and Ras and dolichol-mediated glycosylation of growth factor receptors. Mevalonic Acid 32-42 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-109 24128347-0 2013 The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase. Mevalonic Acid 30-44 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-116 23471651-2 2013 HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, is the target of statins. Mevalonic Acid 59-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 23471651-2 2013 HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, is the target of statins. Mevalonic Acid 59-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-24 23659452-1 2013 3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase is the rate-limiting activity in the mevalonate pathway that provides essential intermediates for posttranslational modification of growth-associated proteins. Mevalonic Acid 95-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 22960596-3 2013 Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP. Mevalonic Acid 29-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 242-299 21701259-1 2011 The enzyme HMG-CoA reductase (HMGR) has a key regulatory role in the mevalonate pathway for isoprenoid biosynthesis, critical not only for normal plant development, but also for the adaptation to demanding environmental conditions. Mevalonic Acid 69-79 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 11-28 22759742-3 2012 Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD. Mevalonic Acid 23-33 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-97 22759742-3 2012 Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD. Mevalonic Acid 23-33 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-105 22759742-3 2012 Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD. Mevalonic Acid 125-135 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-97 22759742-3 2012 Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD. Mevalonic Acid 125-135 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-105 22981371-3 2012 Mevalonate deprivation induced by competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (e.g., statins) prevents the activation of GTPases, suppresses the expression of the receptor for activation of nuclear factor kappa B (NFkappaB) ligand (RANKL) and activation of NFkappaB and, consequently, inhibits osteoclast differentiation and induces osteoclast apoptosis. Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-117 22310279-2 2012 The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia. Mevalonic Acid 32-42 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-94 22310279-2 2012 The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia. Mevalonic Acid 32-42 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-101 22722993-3 2012 The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC 1.1.1.34) catalyzes the conversion of HMG-CoA to mevalonate, which is the first stage in the cytosolic pathway for biosynthesis of isoprenoid in plants. Mevalonic Acid 104-114 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-44 22722993-3 2012 The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC 1.1.1.34) catalyzes the conversion of HMG-CoA to mevalonate, which is the first stage in the cytosolic pathway for biosynthesis of isoprenoid in plants. Mevalonic Acid 104-114 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-50 22492974-1 2012 Recently we reported that statins, the competitive inhibitors of the key enzyme regulating the mevalonate pathway, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), decrease proliferation of human endometrial stromal (HES) cells. Mevalonic Acid 95-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 115-162 22492974-1 2012 Recently we reported that statins, the competitive inhibitors of the key enzyme regulating the mevalonate pathway, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), decrease proliferation of human endometrial stromal (HES) cells. Mevalonic Acid 95-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 164-169 22433938-1 2012 BACKGROUND: Cholesterol is mainly synthesised in liver and the rate-limiting step is the reduction of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) to mevalonate, a reaction catalysed by HMG-CoA reductase (HMGCR). Mevalonic Acid 152-162 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 188-205 22433938-1 2012 BACKGROUND: Cholesterol is mainly synthesised in liver and the rate-limiting step is the reduction of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) to mevalonate, a reaction catalysed by HMG-CoA reductase (HMGCR). Mevalonic Acid 152-162 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 207-212 22177940-1 2012 The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, a four-electron oxidoreduction that is the rate-limiting step in the synthesis of cholesterol and other isoprenoids. Mevalonic Acid 106-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 11-58 22177940-1 2012 The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, a four-electron oxidoreduction that is the rate-limiting step in the synthesis of cholesterol and other isoprenoids. Mevalonic Acid 106-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-65 22258408-3 2012 Ras activation was induced by the overexpression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), the rate-limiting enzyme of the mevalonate pathway. Mevalonic Acid 134-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-93 22258408-3 2012 Ras activation was induced by the overexpression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), the rate-limiting enzyme of the mevalonate pathway. Mevalonic Acid 134-144 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 95-99 22258408-8 2012 Therefore, reduction of mitochondrial genome content induced overexpression of HMGR through hypoxic to normoxic shift and subsequently the endogenous induction of the mevalonate pathway activated Ras that mediates advanced phenotype. Mevalonic Acid 167-177 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-83 21778231-1 2011 In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD). Mevalonic Acid 133-143 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-78 21778231-1 2011 In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD). Mevalonic Acid 133-143 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-84 21778231-1 2011 In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD). Mevalonic Acid 211-221 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-78 21778231-1 2011 In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD). Mevalonic Acid 211-221 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-84 21778231-2 2011 Here, we studied which mevalonate-derived metabolites signal for HMGR degradation and the ERAD step(s) in which these metabolites are required. Mevalonic Acid 23-33 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-69 21864337-5 2011 METHODS: We used simvastatin (1-15 muM) to inhibit 3-hydroxy-3-methlyglutaryl-coenzyme A (HMG-CoA) reductase which converts HMG-CoA to mevalonate. Mevalonic Acid 135-145 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 51-108 21586555-11 2011 The specificity of HMGCR inhibition to restore osteoblast differentiation of ZGA-treated cultures through the reduction in isoprenoid accumulation was confirmed with the addition of exogenous mevalonate. Mevalonic Acid 192-202 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-24 21701259-1 2011 The enzyme HMG-CoA reductase (HMGR) has a key regulatory role in the mevalonate pathway for isoprenoid biosynthesis, critical not only for normal plant development, but also for the adaptation to demanding environmental conditions. Mevalonic Acid 69-79 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-34 20696928-3 2010 The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids. Mevalonic Acid 4-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-107 21355014-1 2011 BACKGROUND: Mevalonic acid (MVA) is synthesized at an early and rate-limiting step in the biosynthesis of cholesterol by the enzyme hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, and is a useful measure of statin efficacy or treatment. Mevalonic Acid 12-26 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 132-184 20884711-3 2011 DESIGN AND METHODS: We exposed mesenchymal stromal cells to inhibitors, such as fluvastatin, of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase, responsible for the synthesis of mevalonate, the precursor of cholesterol. Mevalonic Acid 182-192 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 100-147 21118482-1 2010 BACKGROUND: PUFAs are potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme catalyzing the conversion of HMGCoA to mevalonate, the rate limiting step in cholesterol biosynthesis. Mevalonic Acid 151-161 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 43-100 20843083-1 2010 Density functional theory was applied to study the binding mode of new flavonoids as possible inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), an enzyme that catalyzes the four-electron reduction of HMGCoA to mevalonate, the committed step in the biosynthesis of sterols. Mevalonic Acid 227-237 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 112-152 20843083-1 2010 Density functional theory was applied to study the binding mode of new flavonoids as possible inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), an enzyme that catalyzes the four-electron reduction of HMGCoA to mevalonate, the committed step in the biosynthesis of sterols. Mevalonic Acid 227-237 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 154-158 20696928-3 2010 The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids. Mevalonic Acid 4-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 109-114 20696928-3 2010 The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids. Mevalonic Acid 16-19 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-107 20696928-3 2010 The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids. Mevalonic Acid 16-19 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 109-114 19500062-5 2009 Statins are lipid lowering drugs, which reduce cholesterol production by inhibiting HMG-CoA reductase, the rate limiting enzyme of the mevalonate pathway. Mevalonic Acid 135-145 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 84-101 20418539-3 2010 We propose a rapid and versatile reverse phase-HPLC method for assaying HMGR activity capable of monitoring the levels of both substrates (HMG-CoA and NADPH) and products (CoA, mevalonate, and NADP(+)) in a single 20 min run with no pretreatment required. Mevalonic Acid 177-187 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 72-76 20016680-2 2010 Statin drugs act as inhibitors of the 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme early in the mevalonate pathway, thereby reducing the endogenous cholesterol synthesis. Mevalonic Acid 115-125 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-94 20581679-1 2010 PURPOSE OF REVIEW: Statins, by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, decrease the synthesis not only of cholesterol but also of nonsteroidal mevalonate derivatives. Mevalonic Acid 163-173 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-89 20019585-2 2010 Statins work by inhibiting HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, thus stopping the conversion of HMG-CoA to mevalonate, which is found in the cholesterol synthesis cascade. Mevalonic Acid 129-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-84 18556704-4 2008 GRP78 induction was abolished by co-treatment with mevalonate and 1,2-bis(o-aminophenoxy)ethane-N, N, N",N"-tetraacetic acid, indicating the involvement of both 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase-dependent and -independent mechanisms. Mevalonic Acid 51-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 161-219 19380384-1 2009 Recent studies have suggested that statins, the inhibitors for 3-hydroxy-3-methyglutaryl (HMG)-CoA reductase in the mevalonate pathway, exhibit anti-inflammatory effects. Mevalonic Acid 116-126 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-108 19053857-8 2008 While mevalonate, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), restored proliferation in LV-treated cells, it failed to do so in RYR-treated cells. Mevalonic Acid 6-16 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 83-88 19346993-1 2009 OBJECTIVE: The rate-limiting activity of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides intermediates essential for growth. Mevalonic Acid 45-55 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-122 17622571-1 2007 Statins are a class of drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMGcoA) reductase, a critical enzyme in the mevalonate pathway. Mevalonic Acid 125-135 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-98 18453621-7 2008 This effect was reversed by mevalonic acid, a downstream metabolite of 3-hydroxy-3-methylglutaryl CoA reductase, confirming that simvastatin"s specific effect is through the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase. Mevalonic Acid 28-42 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 71-111 18625202-1 2008 Simvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway required for the biosynthesis of cholesterol and higher isoprenoids such as geranylgeranyl pyrophosphate (GGPP). Mevalonic Acid 93-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-59 18504457-1 2008 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase produces mevalonate, an important intermediate in the synthesis of cholesterol and essential nonsterol isoprenoids. Mevalonic Acid 67-77 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 18787645-5 2008 Statin, 3-hydroxy-3- methyl-glutaryl (HMG)-CoA reductase inhibitor therapy inhibits conversion of HMG-CoA to mevalonate and lowers plasma CoQ(10) concentrations. Mevalonic Acid 109-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 8-56 17622571-8 2007 Atorvastatin"s effects on MYC were specific to the inhibition of HMGcoA reductase, as treatment with mevalonate, the product of HMG-CoA reductase activity, abrogated these effects and inhibited the ability of atorvastatin to reverse or suppress tumorigenesis. Mevalonic Acid 101-111 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-81 18078012-2 2007 However, because mevalonic acid (MVA), the product of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of HMG-CoA reductase may result in pleiotropic effects, independent of their hypocholesterolemic properties. Mevalonic Acid 17-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 54-114 17601486-1 2007 Previously we demonstrated that secondary products of plant mevalonate metabolism called isoprenoids attenuate 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA translational efficiency and cause tumor cell death. Mevalonic Acid 60-70 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 111-158 17412884-1 2007 Apomine, a 1,1-bisphosphonate-ester with antitumor activity, has previously been reported to strongly down-regulate 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the mevalonate pathway responsible for the prenylation of proteins. Mevalonic Acid 217-227 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 116-163 17272831-3 2007 Mevalonic acid, the product of HMG-CoA reductase, was converted to mevalonolactone (MVL) in an incubation mixture, extracted by a salting-out procedure, derivatized into the mevalonyl-(2-pyrrolidin-1-yl-ethyl)-amide, and then purified using a disposable silica cartridge. Mevalonic Acid 0-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-48 17206841-1 2007 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) catalyzes the formation of mevalonate. Mevalonic Acid 82-92 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 17206841-1 2007 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) catalyzes the formation of mevalonate. Mevalonic Acid 82-92 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 49-53 18078012-2 2007 However, because mevalonic acid (MVA), the product of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of HMG-CoA reductase may result in pleiotropic effects, independent of their hypocholesterolemic properties. Mevalonic Acid 33-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 54-114 16774905-1 2006 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors exert modulatory effects on a number of cell signaling cascades by preventing the synthesis of various isoprenoids derived from the mevalonate pathway. Mevalonic Acid 205-215 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-61 17046548-6 2006 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin inhibited TNF-alpha-induced PAI-1 production by 59%, which was reversed by coincubation with mevalonic acid. Mevalonic Acid 168-182 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-51 16450390-6 2006 All statins" effects were reverted by mevalonic acid, thus suggesting that they were mediated by the inhibition of HMGCoA reductase and were likely to be subsequent to the reduced availability of precursor molecules for RhoA prenylation. Mevalonic Acid 38-52 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 115-131 16857822-3 2006 Lovastatin is a specific and potent inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Mevalonic Acid 123-133 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 49-89 16571871-3 2006 Actions of statins may be related to decreased availability of cholesterol as well as intermediate metabolites of the mevalonate pathway downstream of HMGCR. Mevalonic Acid 118-128 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 151-156 16286544-1 2005 BACKGROUND: Statin drugs (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) reduce the level of cholesterol by inhibiting the synthesis of mevalonate, an intermediary in the cholesterol biosynthetic pathway. Mevalonic Acid 149-159 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 26-73 16436135-1 2006 BACKGROUND: Statins are inhibitors of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase, a key enzyme in mevalonic acid (MVA)-dependent signaling. Mevalonic Acid 108-122 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-90 16436135-1 2006 BACKGROUND: Statins are inhibitors of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase, a key enzyme in mevalonic acid (MVA)-dependent signaling. Mevalonic Acid 124-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-90 16476765-1 2006 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a critical enzyme in the mevalonate pathway that regulates the biosynthesis of cholesterol as well as isoprenoids that mediate the membrane association of certain GTPases. Mevalonic Acid 86-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 16162862-3 2006 Here we look within the domain Bacteria at lateral acquisition of HMGR, whether as a single gene or as part of a mevalonate pathway cluster. Mevalonic Acid 113-123 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-70 16160062-2 2005 However, because statins are potent inhibitors of the mevalonate, which governs diverse cell signaling pathways, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may also result in pleiotropic effects. Mevalonic Acid 54-64 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 127-174 16075407-5 2005 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in cholesterol synthesis from mevalonate and its inhibitors, or statins, can therefore interfere with the above-mentioned consequences of hyperlipidemia. Mevalonic Acid 116-126 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 16048353-2 2005 Statins target several tissues, depending upon their lipophilicity, where they competitively inhibit HMG-CoA reductase, the rate-limiting enzyme for mevalonic acid synthesis and subsequently cholesterol biosynthesis. Mevalonic Acid 149-163 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 101-118 15822054-1 2005 Statins are lipid-lowering agents that specifically, competitively, and reversibly inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in the formation of cholesterol. Mevalonic Acid 205-219 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 91-148 15677697-1 2005 Statins are widely used hypocholesterolemic drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway whose biosynthetic end product is cholesterol. Mevalonic Acid 152-162 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-120 15617098-1 2005 A role for mevalonate in cancer development has long been suggested by findings that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity is elevated in malignant cells. Mevalonic Acid 11-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-142 15274361-3 2004 In the present study we analysed the effect of mevastatin--a novel inhibitor of HMG-COA reductase, the rate-limiting enzyme of the mevalonate pathway--on U266 human myeloma cells. Mevalonic Acid 131-141 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-97 15155733-1 2004 Malignant cells are known to have elevated rates of mevalonate synthesis because of increased levels and catalytic efficiency of 3-hydroxy-3-methylglutaryl-CoA reductase. Mevalonic Acid 52-62 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 129-169 15450939-1 2004 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyzes the formation of mevalonate, a precursor of cholesterol that is also required for cell proliferation. Mevalonic Acid 85-95 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 15861311-3 2004 However, because mevalonic acid is the precursor not only of cholesterol but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may result in pleiotropic effects. Mevalonic Acid 17-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 139-186 15381079-7 2004 The endothelial death and beta4 integrin upregulation by ATV could be reversed by intermediate metabilites of the HMG-CoA reductase pathway mevalonate or GGPP, but not by FPP, suggesting that these effects were results of specific inhibition of the pathway. Mevalonic Acid 140-150 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 114-131 15352124-1 2004 The rate-limiting enzyme for mevalonate synthesis in mammalian cells is 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Mevalonic Acid 29-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 72-129 12526919-1 2003 The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme in the mevalonate biochemical pathway and HMG-CoA reductase inhibitors (statins) show toxicity for certain tumors, including acute myeloid leukemia (AML). Mevalonic Acid 95-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-61 15576975-1 2004 Statins are cholesterol-lowering drugs by inhibiting HMG-CoA reductase, which is a rate limiting enzyme in the mevalonate pathway. Mevalonic Acid 111-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 53-70 15655579-3 2004 In the present study we analysed the effect of mevastatin -- a novel inhibitor of HMG-COA reductase, the rate-limiting enzyme of the mevalonate pathway -- on U266 human myeloma cells. Mevalonic Acid 133-143 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-99 14672267-1 2003 BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors both for cholesterol biosynthesis and for the production of nonsteroidal mevalonate derivatives that are involved in a number of growth-regulatory processes. Mevalonic Acid 107-117 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 12-69 14672267-1 2003 BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors both for cholesterol biosynthesis and for the production of nonsteroidal mevalonate derivatives that are involved in a number of growth-regulatory processes. Mevalonic Acid 227-237 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 12-69 14520514-2 2003 They achieve this through their ability to limit the production of mevalonate via blockade of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase. Mevalonic Acid 67-77 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 94-152 12963986-1 2003 Statins, which have been introduced to the clinic for the treatment of hypercholesterolemia, are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the major rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid (MA). Mevalonic Acid 256-270 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 123-180 12805493-9 2003 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin inhibited the PTHrP(1-36) induction of both NF-kappaB activity and MCP-1 overexpression, and this was reversed by mevalonate. Mevalonic Acid 188-198 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-51 12506040-2 2003 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 91-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 15562337-1 2002 Statins are very potent inhibitors of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis at the mevalonate level. Mevalonic Acid 117-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-55 12538656-3 2003 In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells. Mevalonic Acid 105-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-64 12538656-3 2003 In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells. Mevalonic Acid 105-115 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-70 12538656-3 2003 In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells. Mevalonic Acid 155-165 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-64 12538656-3 2003 In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells. Mevalonic Acid 155-165 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-70 12504097-1 2003 We have examined the effects of tumor necrosis factor alpha (TNF alpha) and its second messenger, ceramide, on HMGCoA reductase, the rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 161-171 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 111-127 12514264-1 2003 The rate-limiting enzyme for mevalonate and cholesterol synthesis in mammalian cells is 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. Mevalonic Acid 29-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 88-138 12514264-3 2003 End products of plant mevalonate metabolism, i.e., plant-derived isoprenoids, also suppress mammalian HMG-CoA reductase. Mevalonic Acid 22-32 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-119 12514264-5 2003 We tested the hypothesis that plant-derived isoprenoids also regulate mammalian HMG-CoA reductase synthesis at a post-transcriptional level by incubating lovastatin-treated C100 cells with mevalonate or a plant-derived isoprenoid (the monoterpenes, limonene, perillyl alcohol or geraniol) either alone or combined with the oxysterol, 25-hydroxycholesterol (25-OH C). Mevalonic Acid 189-199 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 80-97 12514264-6 2003 Mevalonate decreased HMG-CoA reductase synthesis and mRNA levels by 65 and 66%, respectively (P < 0.05). Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-38 12514264-9 2003 A combination of 25-OH C and either mevalonate or any three monoterpenes reduced HMG-CoA reductase mRNA levels (P < 0.05) compared with lovastatin-only treated cells. Mevalonic Acid 36-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 81-98 12514264-10 2003 However, the dual combination of 25-OH C and either mevalonate or a monoterpene resulted in a greater decrease in HMG-CoA reductase synthesis than in mRNA levels. Mevalonic Acid 52-62 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 114-131 12514264-12 2003 Mevalonate enhanced HMG-CoA reductase degradation, but no such effect was observed for the monoterpenes. Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 20-37 12454262-2 2002 HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step of eukaryotic isoprenoid biosynthesis, and is the main target of cholesterol-lowering drugs. Mevalonic Acid 65-75 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 12454262-2 2002 HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step of eukaryotic isoprenoid biosynthesis, and is the main target of cholesterol-lowering drugs. Mevalonic Acid 65-75 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-24 12454262-4 2002 However, during the last years several lines of evidence pointed to the existence of a second isoform of HMGCR localized in peroxisomes, where mevalonate is converted further to farnesyl diphosphate. Mevalonic Acid 143-153 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-110 12523826-0 2002 Detection of the mevalonate pathway in Streptomyces species using the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene. Mevalonic Acid 17-27 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-117 12082550-1 2002 We recently identified 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of the head and neck squamous cell carcinomas (HNSCC) and cervical carcinomas (CC). Mevalonic Acid 114-124 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-80 11960327-1 2002 The statin family of drugs target HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, and have been used successfully in the treatment of hypercholesterolemia for the past 15 years. Mevalonic Acid 85-95 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-51 12467639-2 2003 Statins inhibit HMG CoA reductase, a rate limiting enzyme which catalyses conversion of HMG CoA to mevalonic acid. Mevalonic Acid 99-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-33 14755972-1 2003 3-Hydroxy-3-methyl-coenzyme A reductase (HMG-CoA reductase) which transforms 3-hydroxy-3-methylglutaril-coenzyme A (HMG-CoA) in mevalonate, is the rate limiting enzyme in cholesterol biosynthesis. Mevalonic Acid 128-138 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-58 12656204-1 2002 We have previously shown that alpha-tocotrienol (alpha-T3), a vitamin E analogue and HMG CoA reductase (HMGR) inhibitor, markedly inhibited monocyte-endothelial cell adhesion, a process that was reversed with the addition of mevalonate intermediates involved in protein prenylation. Mevalonic Acid 225-235 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 85-102 12656204-1 2002 We have previously shown that alpha-tocotrienol (alpha-T3), a vitamin E analogue and HMG CoA reductase (HMGR) inhibitor, markedly inhibited monocyte-endothelial cell adhesion, a process that was reversed with the addition of mevalonate intermediates involved in protein prenylation. Mevalonic Acid 225-235 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 104-108 12204108-1 2002 In experimental animals and humans, the concentration of serum mevalonate (MVA), a direct product of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is considered to reflect the activity of whole-body sterol synthesis. Mevalonic Acid 63-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 101-158 11832446-1 2002 BACKGROUND & AIMS: Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase blocks the mevalonate metabolic pathway, which is necessary for the isoprenylation of a number of small guanosine triphosphatases. Mevalonic Acid 106-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-94 11426618-1 2000 We recently identified HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of various retinoic acid responsive cancers. Mevalonic Acid 74-84 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 23-40 11205904-1 2001 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase is the rate-limiting enzyme of the mevalonate pathway, the diverse array of end products of which are vital for a variety of cellular functions, including cholesterol synthesis and cell cycle progression. Mevalonic Acid 86-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-50 11448925-1 2001 The statin family of drugs inhibits 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway, and is used clinically as a safe and effective approach in the control of hypercholesterolemia. Mevalonic Acid 120-130 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-86 11406567-1 2001 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors prevent the conversion of HMG-CoA to mevalonate and thereby inhibit the synthesis of other products derived from this metabolite. Mevalonic Acid 106-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 11160563-7 2001 Tocotrienols have beneficial effects in cardiovascular diseases both by inhibiting LDL oxidation and by down-regulating 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG CoA) reductase, a key enzyme of the mevalonate pathway. Mevalonic Acid 200-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 120-178 10964918-1 2000 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the key regulatory enzyme in the mevalonate (MVA) pathway, is rapidly degraded in mammalian cells supplemented with sterols or MVA. Mevalonic Acid 89-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 10964918-1 2000 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the key regulatory enzyme in the mevalonate (MVA) pathway, is rapidly degraded in mammalian cells supplemented with sterols or MVA. Mevalonic Acid 89-99 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 49-53 12532841-1 1999 In eukaryotes, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a key enzyme that catalyses the synthesis of a precusor of cholesterol as well as non-sterol isoprenoids, mevalonate. Mevalonic Acid 182-192 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-72 10704442-1 2000 The integral ER membrane protein HMG-CoA reductase (HMGR) is a key enzyme of the mevalonate pathway from which sterols and other essential molecules are produced. Mevalonic Acid 81-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 33-50 10704442-1 2000 The integral ER membrane protein HMG-CoA reductase (HMGR) is a key enzyme of the mevalonate pathway from which sterols and other essential molecules are produced. Mevalonic Acid 81-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-56 10704442-2 2000 HMGR degradation occurs in the ER and is regulated by mevalonate-derived signals. Mevalonic Acid 54-64 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-4 10665838-2 1999 However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. Mevalonic Acid 17-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 140-187 10399961-2 1999 We have previously shown that blocking the mevalonate pathway with lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, inhibits medulloblastoma proliferation and induces apoptosis in vitro. Mevalonic Acid 43-53 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 106-163 9869647-0 1999 HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells. Mevalonic Acid 137-147 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 9869647-1 1999 The activity of HMG-CoA reductase (HMGR) is tightly regulated, in part through post-transcriptional mechanisms that are mediated by nonsterol products of mevalonate metabolism. Mevalonic Acid 154-164 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-33 9869647-1 1999 The activity of HMG-CoA reductase (HMGR) is tightly regulated, in part through post-transcriptional mechanisms that are mediated by nonsterol products of mevalonate metabolism. Mevalonic Acid 154-164 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-39 10947201-5 2000 Downregulation of HMG-CoA reductase activity in SLOS was supported by measuring plasma levels of mevalonic acid, the immediate product of HMG-CoA reductase. Mevalonic Acid 97-111 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-35 10947201-5 2000 Downregulation of HMG-CoA reductase activity in SLOS was supported by measuring plasma levels of mevalonic acid, the immediate product of HMG-CoA reductase. Mevalonic Acid 97-111 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 138-155 10774794-1 2000 Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity reducing mevalonate synthesis. Mevalonic Acid 106-116 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-87 10698924-1 2000 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the formation of mevalonate, the committed step in the biosynthesis of sterols and isoprenoids. Mevalonic Acid 75-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-40 10698924-1 2000 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the formation of mevalonate, the committed step in the biosynthesis of sterols and isoprenoids. Mevalonic Acid 75-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-46 10698924-2 2000 The activity of HMGR is controlled through synthesis, degradation and phosphorylation to maintain the concentration of mevalonate-derived products. Mevalonic Acid 119-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-20 11043510-1 2000 We determined the genomic structure of the human gene encoding 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate and is the rate-limiting and major regulatory enzyme in sterol biosynthesis. Mevalonic Acid 167-177 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-120 10563217-1 1999 BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors for cholesterol biosynthesis and the production of non-steroidal mevalonate derivatives that are involved in a number of growth-regulatory processes. Mevalonic Acid 117-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 12-78 10563217-1 1999 BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors for cholesterol biosynthesis and the production of non-steroidal mevalonate derivatives that are involved in a number of growth-regulatory processes. Mevalonic Acid 229-239 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 12-78 10506194-2 1999 L-90 cells massively accumulate HMGR, a result of >10-fold amplification of the gene and 40-fold rise in mRNA, and also overexpress other enzymes of the mevalonate pathway. Mevalonic Acid 156-166 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 32-36 10460692-1 1999 Pure and mixed isoprenoid end products of plant mevalonate metabolism trigger actions that suppress 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity. Mevalonic Acid 48-58 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 100-157 10374838-3 1999 However, while the addition of mevalonate, the product of HMG-CoA-reductase, circumvented the inhibition by lovastatin it had no reversing effect on the inhibition by L-ascorbic acid. Mevalonic Acid 31-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-75 10075142-1 1999 BACKGROUND: The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation. Mevalonic Acid 123-133 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-73 9445257-7 1998 The inhibition of the stimulatory effect of BP II on cholesterol production by genistein in hyperapoB cells may be mediated through 3-hydroxy 3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme of cholesterol biosynthesis, since the rate of incorporation of [14C]acetate, but not [3H]mevalonate, into unesterified cholesterol was decreased by genistein in the hyperapoB cells. Mevalonic Acid 296-306 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 132-179 9610772-8 1998 The study was extended by examining plasma levels of mevalonic acid and lathosterol, both markers of cholesterol biosynthesis, in response to cholestyramine, a bile acid sequestrant that is known to up-regulate HRase. Mevalonic Acid 53-67 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 211-216 9799804-9 1998 In addition, we have also recently demonstrated that the UT2 cells express a 90 kDa HMG-CoA reductase protein that is localized exclusively in peroxisomes, and is up-regulated when the cells are grown in the absence of added mevalonate. Mevalonic Acid 225-235 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 84-101 9237866-0 1997 Posttranscriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in lens epithelial cells by mevalonate-derived nonsterols. Mevalonic Acid 110-120 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-81 8970163-3 1996 The degradation of HMG-R is regulated as part of feedback control of the mevalonate pathway. Mevalonic Acid 73-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-24 9250604-3 1997 In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis. Mevalonic Acid 172-182 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 97-113 9501689-3 1997 HMG-CoA reductase catalyses the reduction of HMG-CoA o mevalonate and is rate-limiting step in cholesterol biosynthesis pathway. Mevalonic Acid 55-65 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 8908154-1 1996 Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, inhibits the synthesis of mevalonic acid and is widely used as an anti-atherosclerotic drug. Mevalonic Acid 113-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-85 7482033-0 1995 Mevalonate regulates polysome distribution and blocks translation-dependent suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA: relationship to translational control. Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 91-138 8810339-1 1996 The endoplasmic reticulum (ER) membrane protein 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is subject to regulated degradation when cells are presented with an excess of sterols or mevalonate. Mevalonic Acid 196-206 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-105 8663239-2 1996 Depletion of mevalonic acid (MVA), obtained by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase using lovastatin, depressed the biosynthesis of dolichyl-phosphate and the rate of N-linked glycosylation and caused growth arrest in the melanoma cell line SK-MEL-2. Mevalonic Acid 13-27 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 61-118 8626470-0 1996 Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. Mevalonic Acid 91-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-61 8626470-1 1996 We have previously reported that degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in the isoprenoid pathway leading to cholesterol production, can be accelerated in cultured cells by the addition of farnesyl compounds, which are thought to mimic a natural, nonsterol mevalonate metabolite(s). Mevalonic Acid 307-317 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-95 8562480-7 1995 When endogenous and transfected reductase activity was bypassed by the addition of mevalonate and compactin, a competitive inhibitor, the filamentous actin distribution in HMG-CoA reductase-transfected cells became very similar to that of control cells, demonstrating the role of exogenous HMG-CoA reductase activity in this process. Mevalonic Acid 83-93 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 172-189 8562480-7 1995 When endogenous and transfected reductase activity was bypassed by the addition of mevalonate and compactin, a competitive inhibitor, the filamentous actin distribution in HMG-CoA reductase-transfected cells became very similar to that of control cells, demonstrating the role of exogenous HMG-CoA reductase activity in this process. Mevalonic Acid 83-93 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 290-307 7641798-1 1995 Cells treated with compactin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the rate-limiting step of the mevalonate pathway, are arrested prior to the DNA synthesis (S) phase of the cell cycle. Mevalonic Acid 162-172 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-103 7482033-1 1995 We reported previously that 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis is regulated at the translational level by mevalonate. Mevalonic Acid 129-139 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-75 7964176-2 1994 The mevalonate pathway, which starts with the synthesis of mevalonate by HMGR, has more branch pathways in plants than in most other organisms, leading to a tremendous variety of isoprenoid products. Mevalonic Acid 4-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-77 7723786-1 1995 Activity of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the key enzyme in the biosynthesis of steroids and polyisoprenoids in mammalian cells, has been detected in both the bloodstream form and the culture-adapted procyclic form of Trypanosoma brucei (3.7 +/- 0.6 and 12.7 +/- 1.8 pmol mevalonate produced min-1 (mg cell protein)-1, respectively). Mevalonic Acid 296-306 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 12-64 8021239-0 1994 Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Mevalonic Acid 59-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 118-165 7964176-2 1994 The mevalonate pathway, which starts with the synthesis of mevalonate by HMGR, has more branch pathways in plants than in most other organisms, leading to a tremendous variety of isoprenoid products. Mevalonic Acid 59-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 73-77 7710260-6 1994 In conclusion, hyperinsulinemia in the presence of euglycemia acutely decreases the circulating levels of mevalonic acid, the immediate product of HMG CoA reductase in the cholesterol pathway. Mevalonic Acid 106-120 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 147-164 8198025-6 1994 The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation, and thus may control the neointimal response, which forms the kernel of restenosis. Mevalonic Acid 97-107 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-61 8406993-0 1993 Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Mevalonic Acid 14-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-77 8406993-1 1993 HMG-CoA reductase catalyzes the synthesis of mevalonate, a crucial intermediate in the biosynthesis of cholesterol and non-sterol isoprenoid compounds essential for cell growth. Mevalonic Acid 45-55 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 8097083-5 1993 These observations suggest that the initial phase of mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity was governed primarily by post-translational processes. Mevalonic Acid 53-63 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 88-135 8216498-0 1993 Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Mevalonic Acid 21-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 112-129 8352528-6 1993 Following a 25-hydroxycholesterol treatment as short as 4 h, the onset of DNA synthesis was delayed, indicating that a certain level of HMG CoA reductase activity (= mevalonate synthesis) in the early and mid stage of the prereplicative phase is required for the transduction of the signal leading to initiation of DNA synthesis. Mevalonic Acid 166-176 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 136-153 1712015-11 1991 In mAb is associated with PKC-dependent induction of HMG-CoA reductase which, in turn, leads to the generation of mevalonic acid and its metabolites, one or more of which play a requisite role in cell cycle progression. Mevalonic Acid 114-128 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 53-70 8476209-3 1993 Following addition of mevalonate to cells arrested by HMG CoA reductase inhibitors, the depression of N-linked glycosylation was overcome and the cells initiated DNA synthesis. Mevalonic Acid 22-32 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 54-71 1487489-5 1992 They also responded to mevinolin (an HMG CoA reductase inhibitor) by a similar G1-block, indicating that a mevalonate-derived product is involved in the G1-located cell cycle control of HDF. Mevalonic Acid 107-117 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-54 1471162-7 1992 The 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase (the rate-limiting reaction in cholesterol biosynthesis) is the enzyme which catalyzes the conversion of HMGCoA to mevalonic acid. Mevalonic Acid 169-183 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-53 1503903-2 1992 The effect of ONC alone and in combination with lovastatin (LVT), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of mevalonate (MVA) and cholesterol synthesis pathway, in three human tumour cell lines ASPC-1 pancreatic, A-549 lung, and HT-520 lung carcinomas, has been presently studied. Mevalonic Acid 167-177 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-139 1349377-4 1992 In-vivo and cell-culture experiments have shown that lowering the plasma cholesterol concentration or intervening in the mevalonate pathway with 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitors decreases tumour growth. Mevalonic Acid 121-131 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 145-191 1580550-1 1992 The proliferative rate as well as the activity of 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase, which regulates de novo synthesis of mevalonate, was comparable in the two human breast cancer cell lines Hs578T and MDA-231 when cultured in the presence of serum. Mevalonic Acid 139-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 50-100 1346397-6 1992 Surprisingly, the addition of A23187 to THP-1 cells incubated in the presence of 25-hydroxycholesterol and mevalonic acid also led to significant increases in the mRNA levels for HMG-CoA reductase and HMG-CoA synthase. Mevalonic Acid 107-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 179-196 1657912-7 1991 Mevalonate, at concentrations that did not decrease HMGR activity, was able to restore the inhibiting effect of SKF 104976 on HMGR activity. Mevalonic Acid 0-10 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 126-130 1657912-9 1991 These findings suggest that upon inhibition of 14 alpha DM by SKF 104976, a mevalonate-derived precursor regulates HMGR activity, even when the sterol synthetic rate is considerably reduced and when HMGR protein levels are very high. Mevalonic Acid 76-86 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 115-119 1657912-9 1991 These findings suggest that upon inhibition of 14 alpha DM by SKF 104976, a mevalonate-derived precursor regulates HMGR activity, even when the sterol synthetic rate is considerably reduced and when HMGR protein levels are very high. Mevalonic Acid 76-86 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 199-203 1908464-1 1991 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the biosynthesis of cholesterol and isoprenoids, is subject to rapid degradation which is regulated by mevalonate (MVA)-derived metabolic products. Mevalonic Acid 200-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 1908464-1 1991 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the biosynthesis of cholesterol and isoprenoids, is subject to rapid degradation which is regulated by mevalonate (MVA)-derived metabolic products. Mevalonic Acid 212-215 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 2335559-4 1990 Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin (lovastatin) specifically depletes endogenous isoprenoid pools and inhibits the conversion of prelamin A to lamin A. Prelamin A processing is also blocked by mevalonate starvation of Mev-1, a CHO cell line auxotrophic for mevalonate. Mevalonic Acid 233-243 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-61 1943491-2 1991 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is the enzyme which catalyzes mevalonic acid synthesis. Mevalonic Acid 88-102 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 2246324-2 1990 Earlier, we reported that treatment of NK cells with an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase such as compactin or lovastatin significantly abrogates the in vitro killing of a susceptible human erythroleukemic cell line and that this inhibition can be completely reversed by 2 hr of exposure to mevalonate (J. Mevalonic Acid 328-338 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 69-126 2335559-4 1990 Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin (lovastatin) specifically depletes endogenous isoprenoid pools and inhibits the conversion of prelamin A to lamin A. Prelamin A processing is also blocked by mevalonate starvation of Mev-1, a CHO cell line auxotrophic for mevalonate. Mevalonic Acid 297-307 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-61 34711640-3 2022 ETP-ALLs showed increased biosynthesis of phospholipids and sphingolipids, and were specifically sensitive to inhibition of 3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 206-216 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 124-164 34884489-8 2021 NRF3 also promotes mevalonate biosynthesis by inducing SREBP2 and HMGCR gene expression, and reduces the intracellular levels of neural fatty acids by inducing GGPS1 gene expression. Mevalonic Acid 19-29 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-71 34711640-3 2022 ETP-ALLs showed increased biosynthesis of phospholipids and sphingolipids, and were specifically sensitive to inhibition of 3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. Mevalonic Acid 206-216 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 166-171 34627266-7 2021 Further experiments showed that SIM could inhibit the expression of HMGCR to downregulate the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4), thereby inducing cancer cell ferroptosis. Mevalonic Acid 94-104 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 68-73 35538051-2 2022 Statins inhibit HMG-CoA reductase (HMGCR), which converts the metabolite HMG-CoA into mevalonate. Mevalonic Acid 86-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-33 35538051-2 2022 Statins inhibit HMG-CoA reductase (HMGCR), which converts the metabolite HMG-CoA into mevalonate. Mevalonic Acid 86-96 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-40 35321818-3 2022 Although the primary target of statins is the inhibition of HMG-CoA reductase (HMGR), the rate-limiting enzyme in cholesterol biosynthesis, statins exhibit many pleiotropic effects downstream of the mevalonate pathway. Mevalonic Acid 199-209 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-77 35321818-3 2022 Although the primary target of statins is the inhibition of HMG-CoA reductase (HMGR), the rate-limiting enzyme in cholesterol biosynthesis, statins exhibit many pleiotropic effects downstream of the mevalonate pathway. Mevalonic Acid 199-209 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-83 35359411-9 2022 Interestingly, the expression of some genes of the mevalonate and cholesterol synthesis such as HMGS1, HMGCR, IDI1, SQLE, MSMO1, SREBF1, and SOAT1 was up-regulated by CDPs exposure. Mevalonic Acid 51-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-108 35470784-1 2022 Human 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; EC 1.1.1.34) catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, which has been defined as the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus playing a critical role in cellular cholesterol homeostasis. Mevalonic Acid 150-164 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 6-53 35470784-1 2022 Human 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; EC 1.1.1.34) catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, which has been defined as the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus playing a critical role in cellular cholesterol homeostasis. Mevalonic Acid 150-164 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-60 2568358-2 1989 Addition of either delipidized serum and mevinolin or low density lipoprotein, 25-hydroxycholesterol, or mevalonic acid to HepG2 cells resulted in rapid changes both in the levels of the mRNAs and in the rates of synthesis of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, HMG-CoA reductase, and farnesyl pyrophosphate synthetase (prenyltranferase). Mevalonic Acid 105-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 284-301 35193687-10 2022 RPPA analysis and carbon-13 tracing analysis in these melanoma cells showed that IACS treatment decreased metabolic fuel utilization for fatty acid metabolism, but increased substrate availability for activation of the mevalonate pathway by HMGCR, creating a dependence on this pathway. Mevalonic Acid 219-229 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 241-246 2795368-10 1989 The finding of HMG-CoA reductase provides an enzymatic mechanism for the intermediate conversion of HMG-CoA to mevalonic acid that would be needed for acetate-dependent isoprenoid lipid synthesis by adult H. diminuta. Mevalonic Acid 111-125 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-32 2904178-1 1988 Two enzymes of mammalian cellular mevalonate biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase and HMG-CoA reductase, have been shown to be regulated by exogenous sterols. Mevalonic Acid 34-44 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 120-137 3278736-10 1988 Both mevalonate and cholesterol auxotrophs have been isolated with the BUdR technique and have proven useful for elucidation of the early steps in cholesterol biosynthesis, particularly for the ratelimiting enzyme HMG-CoA reductase. Mevalonic Acid 5-15 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 214-231 2848511-0 1988 Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites. Mevalonic Acid 127-137 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-54 6397554-2 1984 Mevalonic acid, the product of HMG-CoA reductase, the rate-limiting enzyme of cholesterogenesis, is now known to serve at least two functions in the cell cycle. Mevalonic Acid 0-14 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-48 4065145-0 1985 The effect of mevalonate on 3-hydroxy-3-methylglutaryl-CoA reductase activity and the absolute rate of cholesterol biosynthesis in human monocyte-derived macrophages. Mevalonic Acid 14-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-68 3113763-1 1987 HMG-CoA reductase catalyzes the conversion of hydroxymethylglutarate to mevalonate, an important early rate-limiting step in the cholesterol biosynthesis pathway. Mevalonic Acid 72-82 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 3850904-1 1985 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyzes the formation of mevalonate, an essential precursor for isoprenoid compounds in mammalian cells. Mevalonic Acid 85-95 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-57 6565710-1 1984 Measurement of mevalonic acid (MVA) concentrations in plasma or 24-h urine samples is shown to be useful in studies of the regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and cholesterol synthesis. Mevalonic Acid 15-29 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 137-194 6147036-2 1984 It is emphasized that the mevalonate synthesis with participation of acetyl-CoA-carboxylase and hydroxymethylglutaryl-CoA-reductase not bound with the endoplasmic reticulum membranes results in formation of the pool of mevalonic acid and other precursors necessary mainly for the organism supply with bile acids under conditions of cholesterol synthesis inhibition. Mevalonic Acid 26-36 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-131 6147036-2 1984 It is emphasized that the mevalonate synthesis with participation of acetyl-CoA-carboxylase and hydroxymethylglutaryl-CoA-reductase not bound with the endoplasmic reticulum membranes results in formation of the pool of mevalonic acid and other precursors necessary mainly for the organism supply with bile acids under conditions of cholesterol synthesis inhibition. Mevalonic Acid 219-233 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-131 6603842-3 1983 The inclusion of 30 mM EDTA and 10 mM mevalonic acid in assays of 3-hydroxy-3-methylglutaryl CoA reductase inactivation in vitro eliminated artifacts generated by the presence of mevalonate kinase. Mevalonic Acid 38-52 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 66-106 6830849-4 1983 The reversal effect by mevalonate was most evident with compactin, a well known competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Mevalonic Acid 23-33 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-152 6831033-1 1983 ML-236B is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the key regulatory enzyme in the sequence that catalyzes the conversion of acetate to mevalonic acid in cholesterol biosynthesis. Mevalonic Acid 183-197 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-95 6572913-1 1983 We describe a cell line, designated C100, that displays a 100-fold increase in the major regulatory enzyme of the cholesterol biosynthetic pathway, 3-hydroxy-3-methylglutaryl-coenzyme A reductase [HMG-CoA; mevalonate:NADP(+) oxido-reductase (CoA-acylating), EC 1.1.1.34]. Mevalonic Acid 206-216 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 148-195 7132293-1 1982 With an aim to study the cholesterol biosynthetic capacity of the leprosy patients, the enzyme Beta hydroxy methyl glutaryl CoA reductase (HMG CoA) has been indirectly determined in the sera of leprosy patients and their family members by assaying the circulating levels of HMG CoA and mevalonate and finding out the ratio between two. Mevalonic Acid 286-296 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 139-146 7132293-1 1982 With an aim to study the cholesterol biosynthetic capacity of the leprosy patients, the enzyme Beta hydroxy methyl glutaryl CoA reductase (HMG CoA) has been indirectly determined in the sera of leprosy patients and their family members by assaying the circulating levels of HMG CoA and mevalonate and finding out the ratio between two. Mevalonic Acid 286-296 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 100-137 6995544-1 1980 The availability of compactin (ML-236B), a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A reductase, has permitted the demonstration of a hitherto unsuspected aspect of mevalonate metabolism and isoprenoid synthesis in cultured mammalian cells. Mevalonic Acid 192-202 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-122 6995544-2 1980 3-Hydroxy-3-methylglutaryl Coenzyme A reductase, the enzyme that synthesizes mevalonate, appears to be regulated through a multivalent feedback mechanism. Mevalonic Acid 77-87 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 6995544-5 1980 The multivalent feedback regulation of 3-hydroxy-3-methylglutaryl Coenzyme A reductase, together with secondary regulatory changes in other enzymes of the sterol synthetic pathway, coordinates the branched pathway of mevalonate metabolism so as to assure a constant supply of cholesterol and nonsterol products. Mevalonic Acid 217-227 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-86 278983-1 1978 The activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) [mevalonate:NADP+ oxidoreductase (CoA-acylating); EC 1.1.1.34] was inhibited by ATP+Mg2+. Mevalonic Acid 96-106 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-74 278983-1 1978 The activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) [mevalonate:NADP+ oxidoreductase (CoA-acylating); EC 1.1.1.34] was inhibited by ATP+Mg2+. Mevalonic Acid 96-106 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 76-93